Home Healthcare Pharmaceuticals Peptide Therapeutics Market

Peptide Therapeutics Market Size, Share & Trends Analysis Report By Application (Cancer, Metabolic, Cardiovascular Disorder, Respiratory, GIT, Anti-infection, Pain, Dermatology, CNS, Renal), By Type (Generic, Innovative), By Type of Manufacturers (In-house, Outsourced), By Route of Administration (Parenteral Route, Oral Route, Pulmonary, Mucosal), By Synthesis Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Peptide Therapeutics Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Cancer
    2. Metabolic
    3. Cardiovascular Disorder
    4. Respiratory
    5. GIT
    6. Anti-infection
    7. Pain
    8. Dermatology
    9. CNS
    10. Renal
  2. Peptide Therapeutics Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Generic
    2. Innovative
  3. Peptide Therapeutics Market, By Type of Manufacturers 2022-2034 (USD MILLION/ Units)
    1. In-house
    2. Outsourced
  4. Peptide Therapeutics Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Parenteral Route
    2. Oral Route
    3. Pulmonary
    4. Mucosal
  5. Peptide Therapeutics Market, By Synthesis Technology 2022-2034 (USD MILLION/ Units)
    1. Solid Phase Peptide Synthesis (SPPS)
    2. Liquid Phase Peptide Synthesis (LPPS)
    3. Hybrid Technology
  6. Regional Peptide Therapeutics Market
    1. North America
      1. North America Peptide Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
      2. North America Peptide Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Generic
        2. Innovative
      3. North America Peptide Therapeutics Market By Type of Manufacturers 2022-2034 (USD MILLION/ Units)
        1. In-house
        2. Outsourced
      4. North America Peptide Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral Route
        2. Oral Route
        3. Pulmonary
        4. Mucosal
      5. North America Peptide Therapeutics Market By Synthesis Technology 2022-2034 (USD MILLION/ Units)
        1. Solid Phase Peptide Synthesis (SPPS)
        2. Liquid Phase Peptide Synthesis (LPPS)
        3. Hybrid Technology
      6. U.S.
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      7. Canada
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
    2. Europe
      1. Europe Peptide Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
      2. Europe Peptide Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Generic
        2. Innovative
      3. Europe Peptide Therapeutics Market By Type of Manufacturers 2022-2034 (USD MILLION/ Units)
        1. In-house
        2. Outsourced
      4. Europe Peptide Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral Route
        2. Oral Route
        3. Pulmonary
        4. Mucosal
      5. Europe Peptide Therapeutics Market By Synthesis Technology 2022-2034 (USD MILLION/ Units)
        1. Solid Phase Peptide Synthesis (SPPS)
        2. Liquid Phase Peptide Synthesis (LPPS)
        3. Hybrid Technology
      6. U.K.
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      7. Germany
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      8. France
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      9. Spain
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      10. Italy
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      11. Russia
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      12. Nordic
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      13. Benelux
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      14. Rest of Europe
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
    3. APAC
      1. APAC Peptide Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
      2. APAC Peptide Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Generic
        2. Innovative
      3. APAC Peptide Therapeutics Market By Type of Manufacturers 2022-2034 (USD MILLION/ Units)
        1. In-house
        2. Outsourced
      4. APAC Peptide Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral Route
        2. Oral Route
        3. Pulmonary
        4. Mucosal
      5. APAC Peptide Therapeutics Market By Synthesis Technology 2022-2034 (USD MILLION/ Units)
        1. Solid Phase Peptide Synthesis (SPPS)
        2. Liquid Phase Peptide Synthesis (LPPS)
        3. Hybrid Technology
      6. China
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      7. Korea
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      8. Japan
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      9. India
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      10. Australia
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      11. Taiwan
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      12. South East Asia
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      13. Rest of Asia-Pacific
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
    4. Middle East and Africa
      1. Middle East and Africa Peptide Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
      2. Middle East and Africa Peptide Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Generic
        2. Innovative
      3. Middle East and Africa Peptide Therapeutics Market By Type of Manufacturers 2022-2034 (USD MILLION/ Units)
        1. In-house
        2. Outsourced
      4. Middle East and Africa Peptide Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral Route
        2. Oral Route
        3. Pulmonary
        4. Mucosal
      5. Middle East and Africa Peptide Therapeutics Market By Synthesis Technology 2022-2034 (USD MILLION/ Units)
        1. Solid Phase Peptide Synthesis (SPPS)
        2. Liquid Phase Peptide Synthesis (LPPS)
        3. Hybrid Technology
      6. UAE
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      7. Turkey
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      8. Saudi Arabia
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      9. South Africa
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      10. Egypt
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      11. Nigeria
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      12. Rest of MEA
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
    5. LATAM
      1. LATAM Peptide Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
      2. LATAM Peptide Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Generic
        2. Innovative
      3. LATAM Peptide Therapeutics Market By Type of Manufacturers 2022-2034 (USD MILLION/ Units)
        1. In-house
        2. Outsourced
      4. LATAM Peptide Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral Route
        2. Oral Route
        3. Pulmonary
        4. Mucosal
      5. LATAM Peptide Therapeutics Market By Synthesis Technology 2022-2034 (USD MILLION/ Units)
        1. Solid Phase Peptide Synthesis (SPPS)
        2. Liquid Phase Peptide Synthesis (LPPS)
        3. Hybrid Technology
      6. Brazil
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      7. Mexico
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      8. Argentina
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      9. Chile
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      10. Colombia
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
      11. Rest of LATAM
        1. Cancer
        2. Metabolic
        3. Cardiovascular Disorder
        4. Respiratory
        5. GIT
        6. Anti-infection
        7. Pain
        8. Dermatology
        9. CNS
        10. Renal
        11. Generic
        12. Innovative
        13. In-house
        14. Outsourced
        15. Parenteral Route
        16. Oral Route
        17. Pulmonary
        18. Mucosal
        19. Solid Phase Peptide Synthesis (SPPS)
        20. Liquid Phase Peptide Synthesis (LPPS)
        21. Hybrid Technology
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.